Open-label, phase II study of ladiratuzumab vedotin (LV) for castration-resistant prostate cancer (SGNLVA-005, trial-in-progress).

被引：1
|
作者：
Sher, Amna Falak [1 ]
Bruce, Justine Yang [2 ]
Gabrail, Nashat Y. [3 ]
Anderson, Ian Churchill [4 ]
Patrikidou, Anna [5 ]
Sanborn, Rachel E. [6 ]
Cho, Jae Yong [7 ]
Lee, Arielle Shebay [8 ]
Lee, Jong-Seok [9 ]
Nott, Louise M. [10 ]
Oh, Do-Youn [11 ]
Oh, Sang Cheul [12 ]
Oh, Sung Yong [13 ]
Wang Yinghui [14 ]
Wang Zejing [14 ]
Guthrie, Troy H. [15 ]
机构：
[1] Stony Brook Univ Hosp, Stony Brook, NY USA
[2] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[3] Gabrail Canc Ctr Res LLC, Canton, OH USA
[4] St Joseph Heritage Healthcare, Santa Rosa, CA USA
[5] Sarah Cannon Res Inst, London, England
[6] Providence Canc Inst, Earle A Chiles Res Inst, Portland, OR USA
[7] Yonsei Univ, Gangnam Severance Hosp, Seoul, South Korea
[8] UT Hlth, HOPE Canc Ctr East Texas, Tyler, TX USA
[9] Seoul Natl Univ, Bundang Hosp, Seongnam Si, South Korea
[10] Royal Hobart Hosp, Hobart, Tas, Australia
[11] Seoul Natl Univ Hosp, Seoul, South Korea
[12] Korea Univ, Guro Hosp, Seoul, South Korea
[13] Dong A Univ Hosp, Busan, South Korea
[14] Seattle Genet Inc, Bothell, WA USA
[15] 21st Century Oncol, Jacksonville, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期
关键词：
D O I：
10.1200/JCO.2021.39.6_suppl.TPS185
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS185
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Open-label, phase II study of ladiratuzumab vedotin (LV) for advanced gastric and gastroesophageal junction adenocarcinoma (SGNLVA-005, Trial-in-Progress).
    Sher, Amna Falak
    Bruce, Justine Yang
    Oh, Sung Yong
    Anderson, Ian Churchill
    Oh, Do-Youn
    Nott, Louise M.
    Lee, Jong-Seok
    Lin, Chia-Chi
    Mehra, Ranee
    Shim, Byoung Yong
    Su, Wu-Chou
    Guthrie, Troy H.
    Gabrail, Nashat Y.
    Sanborn, Rachel E.
    Lee, Arielle Shebay
    Cortinovis, Diego Luigi
    Swiecicki, Paul
    Wang Yinghui
    Wang Zejing
    Cho, Jae Yong
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [2] Sgnlva-005: Open-label, phase II study of ladiratuzumab vedotin (LV) for advanced aerodigestive tract malignancies
    Anderson, Ian Churchill
    Wang, Yinghui
    Wang, Zejing
    Sanborn, Rachel E.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [3] SGNLVA-005: Open-label, phase 2 study of ladiratuzumab vedotin (LV) for aerodigestive tract malignancies
    Guthrie, T.
    Gabrail, N.
    Sher, A.
    Bruce, J.
    Sanborn, R.
    Lee, A.
    Graham, R.
    Tafur, I.
    Pippas, A.
    Wang, Y.
    Wang, Z.
    Anderson, I.
    ANNALS OF ONCOLOGY, 2020, 31 : S164 - S165
  • [4] Open-label, phase II study of ladiratuzumab vedotin (LV) for unresectable locally advanced or metastatic solid tumors
    Arkenau, H-T.
    Guthrie, T.
    Mekhail, T.
    Cortinovis, D.
    Antonuzzo, L.
    Bruce, J. Y.
    Gabrail, N.
    Anderson, I.
    Oh, S. C.
    Oh, S. Y.
    Nott, L.
    Shah, M. A.
    Sanborn, R. E.
    Oh, D-Y.
    Cho, J. Y.
    Lin, C-C.
    Lee, A.
    Wang, Y.
    Wang, Z.
    Sher, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S671 - S672
  • [5] A phase I open-label study using lenalidomide and docetaxel in castration-resistant prostate cancer
    Petrylak, D. P.
    Resto-Garces, K.
    Tibyan, M.
    Mohile, S. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] SGNLVA-002: Single arm, open-label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer
    Cortes, J.
    Diab, S.
    Basho, R. K.
    Oliveira, M.
    Pluard, T.
    Alemany, C.
    Brown-Glaberman, U.
    Meisel, J.
    Boni, V.
    Sinha, R.
    Garcia Estevez, L.
    Ettl, J.
    Kuemmel, S.
    Manso Sanchez, L. M.
    Moon, Y. W.
    Villanueva Vazquez, R.
    Wuerstlein, R.
    Wang, Y.
    Wang, Z.
    Han, H.
    ANNALS OF ONCOLOGY, 2020, 31 : S393 - S393
  • [7] Ketoconazole plus Lenalidomide in patients with Castration-Resistant Prostate Cancer (CRPC): results of an open-label phase II study
    Barata, Pedro C.
    Cooney, Matthew
    Mendiratta, Prateek
    Tyler, Allison
    Dreicer, Robert
    Garcia, Jorge A.
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (06) : 1085 - 1092
  • [8] Ketoconazole plus Lenalidomide in patients with Castration-Resistant Prostate Cancer (CRPC): results of an open-label phase II study
    Pedro C. Barata
    Matthew Cooney
    Prateek Mendiratta
    Allison Tyler
    Robert Dreicer
    Jorge A. Garcia
    Investigational New Drugs, 2018, 36 : 1085 - 1092
  • [9] Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer
    Bratt, O.
    Haggman, M.
    Ahlgren, G.
    Nordle, O.
    Bjork, A.
    Damber, J-E
    BRITISH JOURNAL OF CANCER, 2009, 101 (08) : 1233 - 1240
  • [10] Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer
    O Bratt
    M Häggman
    G Ahlgren
    Ö Nordle
    A Björk
    J-E Damber
    British Journal of Cancer, 2009, 101 : 1233 - 1240
12345